Ro Without Insurance: What Tirzepatide and Semaglutide Really Cost

Does Ro take insurance directly, or is this cash-pay?

It's a hybrid, and the split matters. The $149 membership is always self-pay — Ro does not submit it to any insurance company under any circumstance, covered or not. The medication is different: if your plan covers Wegovy or Zepbound and Ro's team gets a prior authorization approved, the prescription can be filled through your insurance at your plan's copay or coinsurance rather than the cash prices below. Ro's own insurance page states this plainly — coverage runs through your plan at the pharmacy, while the membership fee stays a separate, always-cash line item.

So the honest framing is: you're never fully in-network the way you would be at a primary care office, but you're not necessarily fully cash-pay either. Which bucket you land in depends entirely on what your plan's formulary says about weight-loss GLP-1s — something worth checking before you assume either extreme.

How much Ro costs without insurance: tirzepatide vs. semaglutide

Every Ro patient pays the same base fee regardless of coverage: a $149 monthly membership, discounted to $39 for the first month (or $74/mo if you prepay a full year). That fee buys provider access, coaching, labs when ordered, and the insurance concierge covered below — but it does not include medication. The drug itself is billed separately, and without any insurance offset, here is what the three main GLP-1 options actually run.

• Wegovy Pill (oral semaglutide): around $149/mo — the cheapest branded option on the menu
• Wegovy Pen (injectable semaglutide): around $199/mo for the first two months, then roughly $349/mo at maintenance doses
• Zepbound (tirzepatide, KwikPen via LillyDirect): $299/mo at the 2.5 mg starter dose, $399/mo at 5 mg, and $449/mo at every dose from 7.5 mg through 15 mg

Stack the membership on top of whichever drug you're prescribed and the realistic cash range lands between roughly $298 and $598 a month. Tirzepatide sits at the upper end of that range once you reach a therapeutic dose; oral semaglutide sits at the lower end. Neither number moves for how long you stay on the drug — the membership fee doesn't taper, and Zepbound's dose-tier pricing holds steady once you're titrated up.

Ro's plan list also includes Ozempic, but only off-label and, by Ro's own description, "primarily insurance-dependent." That's a meaningful caveat for a without-insurance page: Ozempic is FDA-approved for type 2 diabetes, not weight loss, so a weight-loss-only prescription without a diabetes diagnosis is unlikely to clear insurance the way Wegovy or Zepbound might, and Ro doesn't publish a cash price for it the way it does for its two on-label options. If you don't have diabetes and don't have coverage, Wegovy or Zepbound are the realistic cash-pay choices at Ro — Ozempic here is really a path for patients pursuing it through insurance, not an off-the-shelf self-pay option.

What Ro's insurance help actually includes

This is the part worth unpacking rather than taking on faith, because "insurance navigation" means very different things across telehealth platforms. At Ro, it's a dedicated concierge team, not a self-service benefits checker: staff verify your specific plan's coverage, prepare and submit the prior authorization paperwork themselves, communicate directly with your insurer, and file an appeal if the initial request is denied. Ro publishes a rough timeline of one to two weeks for the PA decision once submitted, inside a roughly two-to-three-week end-to-end process from verification to answer.

Here's the distinction that matters most before you count on this service: prior authorization only exists to fight for coverage a plan could grant. If your employer's plan carries a blanket exclusion for weight-loss GLP-1s — a written carve-out that applies no matter what your doctor documents — there is no PA to submit and no appeal to win. Ro's concierge team can tell you which situation you're in, but it can't argue your employer into covering a drug class the plan document excludes outright. That distinction is worth getting a straight answer on early, because it decides whether the next section's odds apply to you at all.

What are the realistic odds insurance approves Wegovy or Zepbound?

Ro doesn't publish an approval rate specific to its own patients, and no other GLP-1 telehealth platform reliably does either — so treat any number you see quoted as a general industry figure, not a Ro-specific guarantee. The published, non-Ro data paints a mixed picture. Roughly 40% of commercial insurance plans covered Wegovy as of 2026, up from about 25% in 2023, and nearly all of those require prior authorization plus BMI documentation. Initial PA denial rates for Wegovy run an estimated 35-45% across major insurers, though appeals succeed in a majority of cases when the clinical documentation is thorough. For Zepbound specifically, employer-sponsored plans report an approval rate near 55% once a PA is filed.

The trend line is also moving the wrong way for cash-strapped patients: the Peterson-KFF Health System Tracker has documented employers tightening rather than loosening GLP-1 coverage through 2026, with the share of commercially insured people carrying zero Zepbound coverage climbing from about 51% in 2025 to roughly 60% by mid-2026. Put plainly: coverage is closer to a coin flip than a safe bet for most employer plans, and it's actively getting harder to land for anyone whose employer hasn't already committed to it.

If insurance says no, what do you actually pay?

Exactly the cash numbers from the first section — nothing more, nothing less. A denied PA doesn't trigger a penalty price; it just means the $149 membership plus $149-$449/mo in medication is the bill, the same as if you'd never tried for coverage at all. Run the full year and that's roughly $3,600 to $7,200 depending on which drug and dose you land on, weighted toward the lower end for oral semaglutide and the higher end for maintenance-dose tirzepatide.

That's worth sitting with before you enroll: the worst case isn't some inflated penalty rate, it's simply the retail price you'd be quoted on day one anyway. The question isn't really "what if I get denied" — it's whether you can carry $300-$600 a month for as long as you're on the drug if the coin flip in the section above doesn't land your way.

Is Ro's insurance help worth more than a brand offering none at all?

Compare Ro against a platform like Hers, which is explicit that every plan is cash-pay with no insurance-billing path whatsoever. If your plan has any realistic shot at covering Wegovy or Zepbound — meaning it's not an outright exclusion — Ro's concierge team costs nothing extra beyond the same membership fee a no-insurance platform would charge anyway, and it gives you a real attempt at turning a $300-$450 medication line into a copay. That asymmetry (free upside, no downside) is the actual case for choosing Ro over a brand that doesn't try.

Where that edge disappears: if you already know your plan carries a blanket weight-loss exclusion, or you're on Medicaid (Ro doesn't accept it) or Medicare without a qualifying Part D plan, the cash outcome at Ro and at Hers converges to roughly the same number. In that scenario, the decision comes down to medication menu and platform fit rather than insurance support — worth reading both reviews before you choose on price alone.

Can FSA or HSA money close the gap if insurance denies you?

Partially, and with a real caveat worth knowing upfront. Prescribed GLP-1 medication is a category that generally qualifies as an eligible medical expense under FSA and HSA rules, the same way any prescription drug would. Ro's own site, however, doesn't publish a clear statement on whether the $149 membership fee itself is processed as FSA/HSA-eligible at checkout — that piece is genuinely murkier than the medication charge, and third-party sources disagree on it. Before you plan around it, call your FSA or HSA administrator and confirm both pieces: whether the medication line qualifies (it likely does) and whether the membership fee does too (confirm directly — don't assume).

If it does qualify, paying with pre-tax dollars effectively discounts the bill by your marginal tax rate without changing anything at checkout — a real, if partial, offset against a denied claim.

Is Ro worth it if you don't have GLP-1 coverage?

If there's any realistic chance your plan covers Wegovy or Zepbound — meaning you're not staring at a written exclusion — yes, the concierge service is worth using before you write off Ro on price. It costs nothing beyond the membership you'd pay anyway, and roughly four in ten commercial plans now cover Wegovy in some form, with appeals reversing a majority of initial denials when the paperwork is solid. Ro doing that legwork for you, rather than you doing it yourself on hold with your insurer, is genuinely the differentiator.

If you already know the answer is no — a flat employer exclusion, Medicaid, or a Part D plan without the current GLP-1 pill benefit — then the decision is really about the $298-$598/mo cash price and whether FDA-approved brand-name medication, labs, and coaching bundled into that membership are worth the premium over a compounded-first competitor. The full Ro review covers how the program works day to day, and the Ro cost breakdown runs the complete dose-by-dose math and stacks it against other platforms.